Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients

Tomas Duffy, Margarita Bisio, Jaime Altcheh, Juan Miguel Burgos, Mirta Diez, Mariano Jorge Levin, Roberto Rene Favaloro, Hector Freilij, Alejandro Gabriel Schijman, Tomas Duffy, Margarita Bisio, Jaime Altcheh, Juan Miguel Burgos, Mirta Diez, Mariano Jorge Levin, Roberto Rene Favaloro, Hector Freilij, Alejandro Gabriel Schijman

Abstract

Background: This report describes a real-time PCR (Q-PCR) strategy to quantify Trypanosoma cruzi (T. cruzi) DNA in peripheral blood samples from Chagas disease patients targeted to conserved motifs within the repetitive satellite sequence.

Methodology/principal findings: The Q-PCR has a detection limit of 0.1 and 0.01 parasites/mL, with a dynamic range of 10(6) and 10(7) for Silvio X10 cl1 (T. cruzi I) and Cl Brener stocks (T. cruzi IIe), respectively, an efficiency of 99%, and a coefficient of determination (R(2)) of 0.998. In order to express accurately the parasitic loads: (1) we adapted a commercial kit based on silica-membrane technology to enable efficient processing of Guanidine Hydrochloride-EDTA treated blood samples and minimize PCR inhibition; (2) results were normalized incorporating a linearized plasmid as an internal standard of the whole procedure; and (3) a correction factor according to the representativity of satellite sequences in each parasite lineage group was determined using a modified real-time PCR protocol (Lg-PCR). The Q-PCR strategy was applied (1) to estimate basal parasite loads in 43 pediatric Chagas disease patients, (2) to follow-up 38 of them receiving treatment with benznidazole, and (3) to monitor three chronic Chagas heart disease patients who underwent heart-transplantation and displayed events of clinical reactivation due to immunosupression.

Conclusion/significance: All together, the high analytical sensitivity of the Q-PCR strategy, the low levels of intra- and inter-assay variations, as well as the accuracy provided by the Lg-PCR based correction factor support this methodology as a key laboratory tool for monitoring clinical reactivation and etiological treatment outcome in Chagas disease patients.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Dynamic range of the T.…
Figure 1. Dynamic range of the T. cruzi satellite DNA based Q-PCR.
Results are expressed as the number of parasites per milliliter of blood and represent the average of 5 independent experiments. Slope = −3.35. Efficiency = 99%. Dynamic range: 0.01–105 p/mL. R square: 0.998. C(t): cycle threshold.
Figure 2. Melting curve analysis of satellite…
Figure 2. Melting curve analysis of satellite amplicons from reference stocks.
Group I satellite amplicons show melting temperatures above 85°C, whereas Group II render amplification products with melting temperatures below 85°C.
Figure 3. Parasitic loads in peripheral blood…
Figure 3. Parasitic loads in peripheral blood samples from pediatric patients.
(A) Association between basal parasitic loads and patients' ages in 43 pediatric cases. Coefficient of correlation: −0.5832; P

Figure 4. Follow-up of Chronic Chagas heart…

Figure 4. Follow-up of Chronic Chagas heart disease patients after heart transplantation.

Parasitic loads in…

Figure 4. Follow-up of Chronic Chagas heart disease patients after heart transplantation.
Parasitic loads in peripheral blood samples of Chronic Chagas heart disease patients with clinical reactivation due to immunosupression after heart transplantation. * Time of diagnosis of clinical reactivation and etiological treatment.
Figure 4. Follow-up of Chronic Chagas heart…
Figure 4. Follow-up of Chronic Chagas heart disease patients after heart transplantation.
Parasitic loads in peripheral blood samples of Chronic Chagas heart disease patients with clinical reactivation due to immunosupression after heart transplantation. * Time of diagnosis of clinical reactivation and etiological treatment.

References

    1. WHO. World Health Organization, Report of the scientific working group on Chagas disease. 2007
    1. WHO. 2002. pp. 1–109. World Health Organization, Technical Reports Series 905.
    1. Macedo AM, Pena SD. Genetic variability of Trypanosoma cruzi: implications for the pathogenesis of Chagas disease. Parasitol Today. 1998;14:119–124.
    1. Anonymous. Recommendations from a satellite meeting. International Symposium to commemorate the 90th anniversary of the discovery of Chagas disease. Mem Inst Oswaldo Cruz. 1999;94:429–432.
    1. Brisse S, Barnabe C, Tibayrenc M. Identification of six Trypanosoma cruzi phylogenetic lineages by random amplified polymorphic DNA and multilocus enzyme electrophoresis. Int J Parasitol. 2000;30:35–44.
    1. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003;19:495–501.
    1. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J. 1994;127:151–162.
    1. Elias MC, Vargas NS, Zingales B, Schenkman S. Organization of satellite DNA in the genome of Trypanosoma cruzi. Mol Biochem Parasitol. 2003;129:1–9.
    1. Martins C, Baptista CS, Ienne S, Cerqueira GC, Bartholomeu DC, Zingales B. Genomic organization and transcription analysis of the 195-bp satellite DNA in Trypanosoma cruzi. Mol Biochem Parasitol. 2008;160:60–64.
    1. Vargas N, Pedroso A, Zingales B. Chromosomal polymorphism, gene synteny and genome size in T. cruzi I and T. cruzi II groups. Mol Biochem Parasitol. 2004;138:131–141.
    1. Elias MC, Vargas N, Tomazi L, Pedroso A, Zingales B, et al. Comparative analysis of genomic sequences suggests that Trypanosoma cruzi CL Brener contains two sets of non-intercalated repeats of satellite DNA that correspond to T. cruzi I and T. cruzi II types. Mol Biochem Parasitol. 2005;140:221–227.
    1. Avila HA, Sigman DS, Cohen LM, Millikan RC, Simpson L. Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas' disease. Mol Biochem Parasitol. 1991;48:211–221.
    1. Altcheh J, Biancardi M, Lapeña A, Ballering G, Freilij H. Congenital Chagas disease: experience in the Hospital de Niños, Ricardo Gutiérrez, Buenos Aires, Argentina. Rev Soc Bras Med Trop. 2005;2:41–45.
    1. Diez M, Favaloro L, Bertolotti A, Burgos JM, Vigliano C, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant. 2007;7:1633–1640.
    1. Schijman AG, Altcheh J, Burgos JM, Biancardi M, Bisio M, et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. J Antimicrob Chemother. 2003;52:441–449.
    1. Burgos JM, Altcheh J, Bisio M, Duffy T, Valadares HM, et al. Direct molecular profiling of minicircle signatures and lineages of Trypanosoma cruzi bloodstream populations causing congenital Chagas disease. Int J Parasitol. 2007;37:1319–1327.
    1. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–1599.
    1. Cummings KL, Tarleton RL. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol. 2003;129:53–59.
    1. Piron M, Fisa R, Casamitjana N, López-Chejade P, Puig L, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop. 2007;103:195–200.
    1. Virreira M, Martinez S, Alonso-Vega C, Torrico F, Solano M, et al. Amniotic fluid is not useful for diagnosis of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg. 2006;75:1082–1084.
    1. Freitas JM, Lages-Silva E, Crema E, Pena SD, Macedo AM. Real time PCR strategy for the identification of major lineages of Trypanosoma cruzi directly in chronically infected human tissues. Int J Parasitol. 2006;35:411–417.
    1. Marcet PL, Duffy T, Cardinal MV, Burgos JM, Lauricella MA, et al. PCR-based screening and lineage identification of Trypanosoma cruzi directly from faecal samples of triatomine bugs from northwestern Argentina. Parasitology. 2006;132:57–65.
    1. Liarte DB, Murta SM, Steindel M, Romanha AJ. Trypanosoma cruzi: multiplex PCR to detect and classify strains according to groups I and II. Exp Parasitol. 2009 In press.
    1. Castella V, Dimo-Simonin N, Brandt-Casadevall C, Mangin P. Forensic evaluation of the QIAshredder/QIAamp DNA extraction procedure. Forensic Sci Int. 2006;156:70–73.
    1. Clements DN, Wood S, Carter SD, Ollier WE. Assessment of the quality and quantity of genomic DNA recovered from canine blood samples by three different extraction methods. Res Vet Sci. 2007;85:74–79.
    1. Freilij H, Altcheh J. Congenital Chagas' disease: diagnostic and clinical aspects. Clin Infect Dis. 1995;21:551–555.
    1. Castro AM, Luquetti AO, Rassi A, Rassi GG, Chiari E, Galvão LM. Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi. Parasitol Res. 2002;88:894–900.
    1. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother. 2000;44:150–155.

Source: PubMed

3
Abonnieren